Listen

Description

Episode discussion topics

“The magnitude of the effect we saw was about four times larger than what clinical trials have shown for traditional antidepressants on the market,” says  Alan Davis, Ph.D.,  adjunct assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. “Because most other depression treatments take weeks or months to work and may have undesirable effects, this could be a game changer if these findings hold up in future ‘gold-standard’ placebo-controlled clinical trials.” Psychedelic Treatment with Psilocybin Relieves Major Depression, Study Shows.

"More than a dozen start-ups have jumped into the fray, and the handful of companies that have gone public are collectively valued at more than $2 billion... Compass Pathways, a Nasdaq-listed health care company that has raised $240 million, is conducting 22 clinical trials across 10 countries of psilocybin therapy for treatment-resistant depression."

Your hosts: Michael V. Piscitelli and Raymond Wong Jr.


More info
Learn more and reach out

Special thanks